News
-
-
-
-
PRESS RELEASE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Bausch Health, Canada Inc. announces availability of ARAZLO lotion for acne treatment through BC PharmaCare. ARAZLO offers unique formulation technology to enhance patient tolerability -
PRESS RELEASE
Le traitement de l’acné vulgaire par PrARAZLO(MC) (lotion de tazarotène, 0,045 %) est maintenant accessible aux patients couverts par PharmaCare, le régime d’assurance-médicaments public de la Colombie-Britannique
Bausch Health annonce l'accessibilité de la lotion ARAZLO aux patients de la Colombie-Britannique couverts par PharmaCare pour traiter l'acné. La technologie PRISMATREXMC favorise la tolérabilité du traitement -
PRESS RELEASE
ParetoHealth Welcomes Industry Veteran CFO and Announces Appointment of First Chief Product Officer to Support Continued Growth and Scale
ParetoHealth announces strategic expansion of executive team with new CFO and Chief Product Officer to drive growth in redefining employee health benefits -
-
-
-
PRESS RELEASE
Technical Evaluation by CMAC Introduces LEON’s Cutting-Edge Formulation Technology
Technical Evaluation by CMAC introduces LEON's cutting-edge formulation technology, revolutionizing lipid nanoparticle production for drug delivery. Joint effort with experts proves success in in-vitro and in-vivo tests
